Cardio Diagnostics Q2 FY26 net loss narrows to $1.5 million; revenue falls to $5,360
CDIO•Costs decline across G&A and R&D
General and administrative costs dropped to $1.14 million from $1.3 million, while R&D spend decreased to $162,929 from $178,536.
Cash position and operating cash outflow
Cash rose to $5.59 million at June 30, 2026 from $5.11 million at Dec. 31, 2025; operating cash outflow was $2.9 million for the six months.
Q2 FY26 results show narrower loss on lower revenue
Cardio Diagnostics reported a GAAP net loss of $1.5 million for the quarter ended June 30, 2026, narrowing from $1.68 million a year earlier.
Revenue fell to $5,360 from $7,475; sales and marketing expense edged down to $190,183 from $202,850.
Business updates include new coverage, India rollout and CLIA lab testing
Business updates included first coverage from in May 2026, initial reagent shipments for the India rollout, and patient testing start at its new CLIA lab.
